Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
Light Res Technol ; 55(4-5): 474-486, 2023.
Article in English | MEDLINE | ID: mdl-37469656

ABSTRACT

This article describes the development of a device to investigate the non-visual responses to light: The Light-Dosimeter (lido). Its multidisciplinary team followed a user-centred approach throughout the project, that is, their design decisions focused on researchers' and participants' needs. Together with custom-made mountings and the software Lido Studio, the lidos provide researchers with a holistic solution to record participants' light exposure in the near-corneal plane in laboratory settings and under real-world conditions. Validation measurements with commercial equipment were deemed satisfying, as was the combining with data from other devices. The handling of the lidos and mountings and the use of the software Lido Studio during the trial period by various researchers and participants were successful. Despite some limitations, the lidos can help advance research on the non-visual responses to light over the coming years.

2.
Endocrine ; 73(1): 203-208, 2021 07.
Article in English | MEDLINE | ID: mdl-33484412

ABSTRACT

PURPOSE: To evaluate the prevalence of less severe hypercortisolism (LSH) in fractured patients, and its association with hypertension, hyperglicemia, dyslipidemia, and obesity. METHOD: From July 2015 to October 2018 we enrolled all fractured patients admitted in our outpatient center for metabolic bone diseases, after exclusion of patients with secondary osteoporosis apart from diabetes and taking drugs known to affect bone metabolism. In all enrolled patients we collected data regarding gonadal status, history of diabetes, high blood pressure, dyslipidemia, and measured blood pressure, lipid profile, fasting glycaemia. Bone mass was measured with DXA at lumbar spine and femoral neck and the presence of fractures was evaluated with X-ray of thoracic and lumbar spine. All patients performed twice, 1 mg overnight dexametasone suppression test (DST) and, as confirmatory, 2day low-dose DST for diagnosing hypercortisolism. RESULTS: We enrolled 101 fractured patients (75 females, 26 males), aged 65 ± 10.3 years. Five out of 101 (5.0%) patients were diagnosed as LSH. Fifty-five (54.5%) out of 101 were hypertensive, 57 (56.4%) dyslipidemic, 17 (16.8%) hyperglicaemic, 28(27.7%) obese patients. LSH tended to be associated to blood hypertension [5/5 vs 50/96 (Fisher exact test, p = 0.06) hypertensive patients]. Four out five LSH patients were hypogonadic. CONCLUSIONS: Our study confirms that a nonnegligible percentage of fractured subjects actually presents an unrecognized hypercortisolism. Accordingly, regardless of age, we suggest to screen for hypercortisolism all patients with established osteoporosis and in particular hypertensive subjects.


Subject(s)
Cushing Syndrome , Fractures, Bone , Osteoporosis , Absorptiometry, Photon , Ambulatory Care Facilities , Bone Density , Cushing Syndrome/complications , Cushing Syndrome/epidemiology , Female , Fractures, Bone/epidemiology , Fractures, Bone/etiology , Humans , Male , Osteoporosis/epidemiology , Osteoporosis/etiology , Prevalence
3.
Transfus Clin Biol ; 28(1): 89-91, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33285299

ABSTRACT

This study shows clinical efficacy and safety profile of an off-label use of caplacizumab for the treatment of immune-mediated thrombotic thrombocytopenic purpura in a middle-aged obese male patient manifesting aphasia, weakness and unconsciousness. Routine blood tests revealed haemolytic anaemia, severe thrombocytopenia (platelet count=20×109/L) and moderate creatinine increase. Diagnosis was based on the clinical judgement and laboratory determinations (undetectable ADAMTS13 activity and presence of anti-ADAMTS13 antibodies). The patient underwent plasma-exchange and an adjunctive treatment with prednisone (1mg/Kg/day), but the occurrence of a refractory and exacerbated form of disease suggested also using rituximab (375mg/m2 weekly for 4 weeks) and caplacizumab as salvage treatments. The caplacizumab was given at 10mg/day subcutaneously without the first intravenous bolus. Because von Willebrand factor inhibition, platelet count recovery and remission of symptoms were achieved, use of caplacizumab with this scheme appeared to be as effective as the approved one. Although this is an off-label use, this case highlights the potential of this new treatment, in terms of drug's efficacy and safety.


Subject(s)
Off-Label Use , Purpura, Thrombotic Thrombocytopenic , Single-Domain Antibodies , ADAMTS13 Protein , Humans , Male , Middle Aged , Obesity/complications , Obesity/drug therapy , Plasma Exchange , Purpura, Thrombotic Thrombocytopenic/drug therapy , Single-Domain Antibodies/therapeutic use
4.
Chronobiol Int ; 37(8): 1201-1206, 2020 08.
Article in English | MEDLINE | ID: mdl-32752886

ABSTRACT

The maternal circadian time structure is incredibly important in the entrainment and programing of the fetal and newborn circadian time structure. Natural sunlight is the primary environmental time cue for entrainment of circadian rhythms, but high-risk pregnant women spend most of their time indoors with artificial light sources and extremely low levels of natural light both during the day and night. Because the daily level, timing, duration of light exposure and its spectral properties are important in maintaining the normal circadian physiology in humans, we aimed to evaluate the environmental lighting conditions in high-risk pregnant women admitted to hospital for long-term stay. About 30 patients were included in the study. Exposed illuminance, color temperature and effective circadian radiation dose were measured and recorded every 10 s by light dosimeters attached to the patients' clothing. We documented the illuminance of 29 pregnant women on 235 inpatient days. Median (IQR) measured illuminance was 70 (28-173) lux in the morning, 124 (63-241) lux in the afternoon, 19 (6-53) lux in the evening and 0 (0-0) lux at the night. Median illuminance for the 235 inpatient days of assessment was below the recommended EU standard of 100 lux-60.5% of the mornings and 42.7% of the afternoons. The women confined to indoor locations rarely achieved an illuminances more than 300 lux in the morning and in the afternoon. Compared to women with outdoor mobility, those confined indoors have a significantly lower illuminance and color temperature, both in the morning and in the afternoon. Our study presents the first information about the dramatically altered environmental lighting conditions experienced by high-risk pregnant women during their hospital stay. Their exposure to light while in the hospital is significantly lower than exposure to natural daylight levels and below the recommended EU standard.


Subject(s)
Melatonin , Pregnancy, High-Risk , Circadian Rhythm , Female , Hospitalization , Humans , Infant, Newborn , Lighting , Pregnancy
5.
Med Vet Entomol ; 34(4): 432-439, 2020 12.
Article in English | MEDLINE | ID: mdl-32671880

ABSTRACT

This study aimed to evaluate the effects of egg dormancy times on susceptibility of larvae of the floodwater mosquito Aedes albifasciatus (Diptera: Culicidae) to parasitism by their natural enemy Strelkovimermis spiculatus (Nematoda: Mermithidae) and on their life history traits. Aedes albifasciatus eggs stored for 2, 4, 6, 8 and 10 months were hatched, and the larvae either exposed to S. spiculatus (treatment group) or not exposed (control group). Egg dormancy time had a negative effect on the retention of parasites, but no effect on the prevalence and intensity of parasitism or the melanization of nematodes. The survival to adulthood of control individuals decreased as dormancy time increased, whereas that of exposed individuals that remained uninfected was constant and low. A trend towards increasing development times with longer dormancy times was detected in the control group, but not in the exposed noninfected group. The results suggest nonconsumptive effects of parasites in exposed but not infected larvae from eggs with short dormancy times. In contrast, the relatively low fitness of larvae from eggs with long dormancy times regardless of their contact with the nematodes may be the result of the nutritional deprivation during the egg stage.


Subject(s)
Aedes , Mermithoidea , Aedes/parasitology , Animals , Host-Parasite Interactions , Mermithoidea/pathogenicity , Nematode Infections/parasitology , Ovum/parasitology , Prevalence
6.
Physiol Behav ; 177: 176-181, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28472669

ABSTRACT

Male rats exhibit reductions in sexual motivation following systemic administration of drugs that inhibit the conversion of testosterone to estrogen, which indicates that estrogen signaling plays a role in male rat sexual motivation. Given that estrogen G-protein coupled receptor 30 (GPR30) is expressed in brain areas that are important for male sexual behaviors and endocrine function, the primary aim of the current study was to examine the role that GPR30 plays in sexual motivation in both sexually naïve and sexually experienced male rats. Following the final treatment with either a GPR30 antagonist (G-15) or vehicle control, male rats were placed into the center chamber of a larger three-chambered testing arena that was designed to assess sexual incentive motivation. A sexually receptive stimulus female rat and a stimulus male rat were individually confined to one of the two smaller chambers that were each separated by a perforated partition from the larger end chambers, which test rats had access to. Relative to vehicle treated rats, male rats treated with G-15 exhibited a reduction in the percentage of time spent in the vicinity of a sexually receptive female rat. Although G-15 reduced sexual incentive motivation independent of sexual experience, only sexually-naïve rats treated with G-15 did not exhibit a preference for the sexually receptive stimulus female rat. Collectively, these results indicate that interference with estrogen signaling at GPR30 reduces sexual motivation and that the lack of preference for a sexually receptive female rat over a male rat following G-15 treatment is abrogated by previous sexual experience.


Subject(s)
Motivation/physiology , Receptors, G-Protein-Coupled/metabolism , Sexual Behavior, Animal/physiology , Animals , Benzodioxoles/pharmacology , Central Nervous System Agents/pharmacology , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Male , Motivation/drug effects , Motor Activity/drug effects , Motor Activity/physiology , Quinolines/pharmacology , Rats, Long-Evans , Receptors, G-Protein-Coupled/antagonists & inhibitors , Sexual Behavior, Animal/drug effects , Social Behavior
7.
Clin Pharmacol Ther ; 101(4): 501-509, 2017 04.
Article in English | MEDLINE | ID: mdl-28074467

ABSTRACT

Elevations in serum bilirubin during drug treatment may indicate global liver dysfunction and a high risk of liver failure. However, drugs also can increase serum bilirubin in the absence of hepatic injury by inhibiting specific enzymes/transporters. We constructed a mechanistic model of bilirubin disposition based on known functional polymorphisms in bilirubin metabolism/transport. Using physiologically based pharmacokinetic (PBPK) model-predicted drug exposure and enzyme/transporter inhibition constants determined in vitro, our model correctly predicted indinavir-mediated hyperbilirubinemia in humans and rats. Nelfinavir was predicted not to cause hyperbilirubinemia, consistent with clinical observations. We next examined a new drug candidate that caused both elevations in serum bilirubin and biochemical evidence of liver injury in rats. Simulations suggest that bilirubin elevation primarily resulted from inhibition of transporters rather than global liver dysfunction. We conclude that mechanistic modeling of bilirubin can help elucidate underlying mechanisms of drug-induced hyperbilirubinemia, and thereby distinguish benign from clinically important elevations in serum bilirubin.


Subject(s)
Carrier Proteins/antagonists & inhibitors , Chemical and Drug Induced Liver Injury/diagnosis , Enzyme Inhibitors/adverse effects , Hyperbilirubinemia/chemically induced , Hyperbilirubinemia/enzymology , Liver/pathology , Animals , Bilirubin/blood , Bilirubin/metabolism , Chemical and Drug Induced Liver Injury/pathology , Computer Simulation , HIV Protease Inhibitors/pharmacokinetics , HIV Protease Inhibitors/toxicity , Humans , Hyperbilirubinemia/pathology , Indinavir/pharmacokinetics , Indinavir/toxicity , Mice , Mice, Knockout , Models, Biological , Nelfinavir/pharmacokinetics , Nelfinavir/toxicity , Pharmacokinetics , Rats , Rats, Gunn , Receptors, Chemokine/antagonists & inhibitors , Systems Biology
9.
Osteoporos Int ; 26(5): 1629-38, 2015 May.
Article in English | MEDLINE | ID: mdl-25619634

ABSTRACT

UNLABELLED: Osteoporosis treatment has low adherence and persistence. This study evaluated if greater patient involvement could improve them. At 12 months, only 114 out of 344 participants were "fully adherent and persistent" (all drug doses taken throughout the study). Only frequency of drug administration had a significant influence on adherence. INTRODUCTION: Osteoporosis affects millions of individuals worldwide. There are now several effective drugs, but adherence to and persistence with treatment are low. This 12-month multicenter, prospective, randomized study evaluated the efficacy of two different methods aimed at improving adherence and persistence through greater patient involvement, compared with standard clinical practice. METHODS: Three hundred thirty-four post-menopausal women, receiving an oral prescription for osteoporosis for the first time, were recruited and randomized into three groups: group 1 (controls, managed according to standard clinical practice) and groups 2 and 3 (managed with greater patient and caregiver involvement and special reinforcements: group 2, instructed to use several different "reminders"; group 3, same "reminders" as group 2, plus regular phone calls from and meetings at the referring Center). All enrolled women had two visits (baseline and 12 months). RESULTS: Of 334 enrolled women, 247 (74%) started the prescribed therapy. Of those who started, 219 (88.7%) persisted in therapy for at least 10 months. At final evaluation, only 114 women were considered as "fully adherent and persistent" (all doses taken throughout the 12 months). There were no significant differences regarding "full adherence" among the three randomized groups. The frequency of drug administration had a significant influence: weekly administration had a >5-fold higher adherence and monthly administration an 8-fold higher adherence (p < 0.0001) than daily administration. CONCLUSIONS: The special effort of devising and providing additional reminders did not prove effective. Additional interventions during the follow-up, including costly interventions such as phone calls and educational meetings, did not provide significant advantages.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Medication Adherence/psychology , Osteoporosis, Postmenopausal/drug therapy , Administration, Oral , Aged , Aged, 80 and over , Bone Density Conservation Agents/therapeutic use , Drug Administration Schedule , Female , Humans , Italy , Medication Adherence/statistics & numerical data , Middle Aged , Osteoporosis, Postmenopausal/psychology , Patient Education as Topic/methods , Patient Participation , Prospective Studies , Telephone
11.
J Endocrinol Invest ; 34(7 Suppl): 23-6, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21985976

ABSTRACT

Carboxyl-terminal PTH fragments (C-PTH), are generated by both direct secretion from parathyroids in relation to serum calcium levels and catabolism of PTH operated by the Kupffer cells in the liver. These molecular fragments have been till recently regarded as inert byproducts of PTH metabolism, since they do not interact with the PTH/PTH-related peptide (rP) receptor, which mediates the classical hormone actions. Current findings instead indicate that C-PTH would interact with a putative C-PTH receptor. This way, C-PTH seem to exert specific effects on calcium homeostasis and bone metabolism, opposite to those of the synthetic agonist of PTH/PTHrP receptor (i.e. PTH 1-34). In vitro and in vivo data actually indicate that C-PTH, by interacting with specific receptors, could have an anti-calcemic action, as well as a pro-apoptotic effect on both osteocytes and osteoclasts. This in turn could result in a reduced activity of the latter cells, with a consequent inhibition of bone resorption.


Subject(s)
Parathyroid Hormone/physiology , Peptide Fragments/physiology , Animals , Apoptosis/drug effects , Bone Resorption/drug therapy , Calcitriol/physiology , Calcium/blood , Calcium/metabolism , Humans , Hypercalcemia/drug therapy , Osteoclasts/drug effects , Osteocytes/drug effects , Parathyroid Hormone/antagonists & inhibitors , Parathyroid Hormone/blood , Peptide Fragments/blood , Receptor, Parathyroid Hormone, Type 1/metabolism , Receptors, Parathyroid Hormone/metabolism
12.
G Chir ; 31(5): 243-5, 2010 May.
Article in English | MEDLINE | ID: mdl-20615369

ABSTRACT

Breast cancer is the most prevalent malignant disease among women, with the exception of non-melanoma skin cancers. Malignant breast tumours metastasise to lungs, bone, liver, lymph nodes and skin, but the literature also reports few cases of unusual metastases such as to the bladder. We present the case of a 57-year-old woman affected by lobular invasive breast cancer and complaining of high urinary frequency with nicturia. To date this is the seventh reported case of isolated metastatis of breast carcinoma to the bladder.


Subject(s)
Breast Neoplasms/pathology , Carcinoma/secondary , Urinary Bladder Neoplasms/secondary , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/drug therapy , Carcinoma/diagnostic imaging , Carcinoma/drug therapy , Fatal Outcome , Female , Humans , Middle Aged , Neoplasm Metastasis , Palliative Care , Ultrasonography , Urinary Bladder Neoplasms/diagnostic imaging , Urinary Bladder Neoplasms/drug therapy
13.
Clin Ter ; 161(1): 77-85, 2010.
Article in Italian | MEDLINE | ID: mdl-20393685

ABSTRACT

Infertility, defined as the inability to conceive despite regular unprotected sexual intercourse over 12 years, affects approximately 10% of the fertile population. The commonest cause of tubal damage is pelvic inflammatory disease (PID), which in the developed world is caused mainly by Chlamydia trachomatis infection. The incidence of tubal damage after one episode of pelvic infection is approximately 12%, 23% after two episodes and 54% after three episodes. Other causes of tubal damage include postsurgical adhesions or endometriosis. Tubal patency can be diagnosed by hysterosalpingography (HSG) or laparoscopy with chromopertubation. Surgery represents the best therapeutic approach for tubal pathology, with a term pregnancy rate of 70% after surgery in selected patients, while the latest results in Italy of assisted reproductive technology (ART) report a live birth rate per cycle of 13.8%. In conclusion, tubal reconstructive surgery remains an important option for many couples and surgery should be the fi rst line approach for a correct diagnosis and treatment of tubal infertility.


Subject(s)
Chlamydia Infections/complications , Chlamydia trachomatis , Fallopian Tube Diseases/diagnosis , Fallopian Tube Diseases/surgery , Infertility, Female/diagnosis , Infertility, Female/surgery , Adnexal Diseases/diagnosis , Adnexal Diseases/surgery , Chlamydia trachomatis/isolation & purification , Fallopian Tube Diseases/complications , Female , Humans , Infertility, Female/microbiology , Pregnancy , Pregnancy Rate
14.
Clin Endocrinol (Oxf) ; 73(2): 161-6, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20184600

ABSTRACT

OBJECTIVE: Subclinical hypercortisolism (SH) has been associated with increased prevalence of hypertension, type 2 diabetes mellitus, dyslipidaemia, central obesity, osteoporosis and vertebral fractures. We aimed to investigate the accuracy of different SH diagnostic criteria in predicting the presence of complications. DESIGN: This was a retrospective study. PATIENTS: We evaluated data from 231 patients (120 women and 111 men) affected with adrenal incidentalomas (AI). MEASUREMENTS: We studied the accuracy of different SH diagnostic criteria (cortisol after 1 mg overnight dexamethasone suppression test - 1mg-DST - at different cut-off such as 49.7, 82.8, 137.9 nmol/l, elevated urinary free cortisol, reduced adrenal corticotroph hormone (ACTH) levels alone or various combination of these parameters) in predicting the concomitant presence of the following three complications: hypertension, type 2 diabetes and vertebral fractures. RESULTS: The criterion characterized by the presence of two of 1mg-DST >82.8 nmol/l, elevated UFC and reduced ACTH struck the best balance between sensitivity and specificity, reaching a good accuracy in predicting the cluster of complications (61.9%; 77.1% and 75.8%, respectively). The presence of this cluster was associated with this criterion (OR 4.75, 95%CI 1.8-12.7, P = 0.002) regardless of gonadal status, body mass index (BMI) and age. CONCLUSIONS: The SH criterion characterized by the presence of two of 1mg-DST >82.8 nmol/l, elevated UFC and reduced ACTH seems the best in predicting the presence of chronic manifestations of subtle cortisol excess.


Subject(s)
Cushing Syndrome/diagnosis , Adenoma/complications , Adenoma/diagnosis , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/diagnosis , Adrenocorticotropic Hormone/analysis , Adrenocorticotropic Hormone/blood , Aged , Cushing Syndrome/complications , Cushing Syndrome/etiology , Cushing Syndrome/pathology , Dexamethasone , Female , Humans , Hydrocortisone , Incidental Findings , Male , Middle Aged , Pituitary-Adrenal Function Tests , Predictive Value of Tests , Retrospective Studies
15.
Minerva Ginecol ; 61(1): 35-43, 2009 Feb.
Article in Italian | MEDLINE | ID: mdl-19204659

ABSTRACT

The role of minimally invasive surgery in the management of gynecologic cancers is continuously expanding. Although few trials have focused on the safety of laparoscopy in oncology, laparoscopy is now widely used for most gynecological malignancies. Laparoscopy is widely used to manage benign ovarian masses, but its role in managing ovarian cancer still needs to be defined. The role of laparoscopy in ovarian cancer surgery may be divided into three following categories: 1) laparoscopic staging of apparent early ovarian cancer; 2) laparoscopic assessment of disease extent and potential for resectability; 3) laparoscopic reassessment, or second-look operation, or rule out recurrence. Laparoscopic approach has shown several advantages like a reduction in operating time, blood loss, hospital stay, and total hospital charges. The limitations of laparoscopic practice include inadequate port-site metastasis, tumour dissemination due to cyst rupture and incomplete staging. In addition, there were limitations in performing extensive laparoscopic sampling of areas of tumor persistence including retroperitoneal lymph nodes. In literature there are no randomized studies assessing the use of laparoscopy in the management of ovarian cancer. Moreover, most of the studies in literature comparing laparoscopy and laparotomy are carried out by surgeons specialized in one of two approaches, so that the results can not be compared.


Subject(s)
Carcinoma/pathology , Carcinoma/surgery , Laparoscopy/methods , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Carcinoma/diagnosis , Clinical Trials as Topic , Evidence-Based Medicine , Female , Humans , Laparoscopy/adverse effects , Length of Stay , Minimally Invasive Surgical Procedures/methods , Neoplasm Seeding , Neoplasm Staging , Ovarian Neoplasms/diagnosis , Treatment Outcome
16.
Minerva Ginecol ; 60(6): 543-50, 2008 Dec.
Article in Italian | MEDLINE | ID: mdl-18981980

ABSTRACT

Urinary incontinence consist in voluntary urine leakage. Female affected in the world are about 200 thousand. Urinary incontinence affect severely women quality of life. There are different kinds of urinary incontinence that can be treated in different ways. We can use pelvic floor rehabilitation, drug therapy, invasive and non-invasive surgical treatment. Different treatments are used for different incontinence types. Periurethral injection is the most common procedure between non-invasive surgery. The most recent bulking agents occasionally determine severe adverse reaction or complication. Frequently we can have just pain during injection and a temporary urine retention. During the latest years we used a lot of bulking agents: bovine collagen, autologous fat, carbon particles, macroplastique, calcium hydroxylapatite, ethylene vinyl alcohol copolymer, dextranomer. Urethral injection have success in 40-90%. We can assert that macroplastique is the most efficacy and safe on the basis of literature data and of our experience data. This surgical procedure, in fact, has good percentage of success in accurately selected patients. In our experience Macroplastique can also be used in oncological patients, in elderly women, in patients with important comorbidity and with high surgical risk with good objective and subjective results.


Subject(s)
Biocompatible Materials/administration & dosage , Urinary Incontinence/therapy , Collagen/administration & dosage , Dextrans/administration & dosage , Durapatite/administration & dosage , Female , Humans , Injections , Patient Selection , Polyvinyls/administration & dosage , Quality of Life , Treatment Outcome , Urethra , Urinary Incontinence/diagnosis , Urinary Incontinence/rehabilitation
17.
Bone Marrow Transplant ; 41(6): 555-62, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18037940

ABSTRACT

Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction therapy. Eligible patients received four induction cycles with FEC 100 (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)). Patients with objective response (N=179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT)) and stem cell support (N=88), or no further treatment (N=91). All patients were observed until disease progression or death. One toxic death occurred after CHUT. Other toxicities were manageable. The response rate at 3 months was higher in the intensification arm: 82.7% (25.3% complete response (CR)) versus 59.2% (14.1% CR) (P=0.0002). Median follow-up was 48 months. Median DFS was 11 and 6.6 months in the intensification and the observation arms, respectively (P=0.0001). There was no survival difference: 33.6 versus 27.3% OS at 3 years (P=0.8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/therapy , Peripheral Blood Stem Cell Transplantation , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/mortality , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Epirubicin/administration & dosage , Epirubicin/adverse effects , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Humans , Middle Aged , Neoplasm Metastasis , Prospective Studies , Survival Analysis , Thiotepa/administration & dosage , Transplantation, Autologous , Treatment Outcome
18.
Ann Oncol ; 18 Suppl 6: vi16-21, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17591813

ABSTRACT

The epidermal growth factor receptor (EGFR) is a member of the erbB family overexpressed in most of the solid tumors. In cancer cells, the overexpression of EGFR correlates with the development and the progression of tumor. Panitumumab is a fully human monoclonal antibody that blocks the extracellular domain of the EGFR and has not been associated with the formation of any antibodies directed against it. This review summarizes on the preclinical and clinical development of panitumumab in human solid tumors. As bevacizumab and cetuximab have been approved for colorectal cancer because of their improvements in progression-free survival and overall survival when associated with chemotherapy, panitumumab represents an interesting molecule which needs more phase III studies to validate its efficacy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/immunology , Colorectal Neoplasms/therapy , Animals , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Colorectal Neoplasms/metabolism , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/biosynthesis , ErbB Receptors/genetics , ErbB Receptors/immunology , Humans , Mice , Panitumumab
19.
Histopathology ; 51(1): 33-9, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17542993

ABSTRACT

AIMS: There is considerable evidence to link cyclooxygenase (COX)-2 to the development of cancer. The aim of this study was to assess COX-2 expression and its subcellular localization in lobular in situ neoplasia (LIN) of the breast and to verify differences in COX-2 expression between different grades of lesions according to the Tavassoli classification. METHODS AND RESULTS: We analysed the expression of COX-2 protein by immunohistochemistry in tissue samples of 51 LIN lesions classified into three grades according to the Tavassoli classification. COX-2 immunostaining was observed in 78.4% of LIN samples and showed a prevalent membranous rather than cytoplasmic pattern. COX-2 was expressed in 16/17 (94.1%) LIN1, 22/25 (88%) LIN2 and 2/9 (22.2%) LIN3. As regards COX-2 expression, a statistically significant difference was found between LIN1 and LIN3 (P = 0.001) and between LIN2 and LIN3 (P =0.001). No difference was found between LIN1 and LIN2. Moreover, a significant negative correlation was found between LIN grade and COX-2 expression (P < 0.0001). CONCLUSIONS: COX-2 is highly expressed in LIN, supporting a role for this protein in the early stage of breast carcinogenesis, representing the rationale for using COX-2 selective inhibitors in the earliest stages of breast cancer.


Subject(s)
Breast Neoplasms/metabolism , Carcinoma, Intraductal, Noninfiltrating/metabolism , Cyclooxygenase 2/metabolism , Neoplasms, Ductal, Lobular, and Medullary/metabolism , Adult , Aged , Aged, 80 and over , Breast/metabolism , Breast/pathology , Breast Neoplasms/classification , Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/classification , Carcinoma, Intraductal, Noninfiltrating/pathology , Cyclooxygenase 2/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Middle Aged , Neoplasms, Ductal, Lobular, and Medullary/classification , Neoplasms, Ductal, Lobular, and Medullary/pathology
20.
J Neurol Neurosurg Psychiatry ; 77(8): 927-32, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16624842

ABSTRACT

OBJECTIVE: To validate nerve-axon reflex-related vasodilatation as an objective method to evaluate C-nociceptive fibre function by comparing it with the standard diagnostic criteria. METHODS: Neuropathy was evaluated in 41 patients with diabetes (26 men and 15 women) without peripheral vascular disease by assessing the Neuropathy Symptom Score, the Neuropathy Disability Score (NDS), the vibration perception threshold (VPT), the heat detection threshold (HDT), nerve conduction parameters and standard cardiovascular tests. The neurovascular response to 1% acetylcholine (Ach) iontophoresis was measured at the forearm and at both feet by laser flowmetry. An age-matched and sex-matched control group of 10 healthy people was also included. RESULTS: Significant correlations were observed between the neurovascular response at the foot and HDT (r(s) = -0.658; p<0.0001), NDS (r(s) = -0.665; p<0.0001), VPT (r(s) = -0.548; p = 0.0005), tibial nerve conduction velocity (r(s) = 0.631; p = 0.0002), sural nerve amplitude (r(s) = 0.581; p = 0.0002) and autonomic function tests. According to the NDS, in patients with diabetes who had mild, moderate or severe neuropathy, a significantly lower neurovascular response was seen at the foot than in patients without neuropathy and controls. A neurovascular response <50% was found to be highly sensitive (90%), with a good specificity (74%), in identifying patients with diabetic neuropathy. CONCLUSION: Small-fibre dysfunction can be diagnosed reliably with neurovascular response assessment. This response is already reduced in the early stages of peripheral neuropathy, supporting the hypothesis that small-fibre impairment is an early event in the natural history of diabetic neuropathy.


Subject(s)
Axons/pathology , Cholinergic Fibers/pathology , Diabetic Neuropathies/diagnosis , Reflex, Abnormal , Aged , Electrophysiology , Female , Humans , Iontophoresis , Male , Middle Aged , Neural Conduction , Neurologic Examination , ROC Curve , Sensitivity and Specificity , Vasodilation
SELECTION OF CITATIONS
SEARCH DETAIL
...